Chewing Gum With Natural Appetite Suppressant Could Treat Obesity

Featured Article
Main Category: Obesity / Weight Loss / Fitness
Also Included In: GastroIntestinal / Gastroenterology;  Pharma Industry / Biotech Industry;  Endocrinology
Article Date: 15 Jan 2007 - 2:00 PDT

email to a friend   printer friendly   opinions  

Scientists at Imperial College, London, are developing an appetite suppressant drug based on a naturally occuring hormone that could be used to tackle obesity and eventually be dispensed as a gum that is chewed after a meal.

The project, which is led by Professor Steve Bloom of the Division of Investigative Science at Imperial College, who has been working on it for some years, has been awarded 2.3 million pounds by the Wellcome Trust which is pouring 91 million pounds (178 million dollars) into research projects to tackle obesity, cancer and other diseases under its Seeding Drug Discovery Initiative.

Professor Bloom has been having difficulty getting commercial sponsorship for the project because the compound he is developing is too large to make into a pill. He leads a team of 30 scientists who are looking at the role played by regulatory peptides and hypothalamic growth hormones and neurotransmitters in controlling energy balance in mammals. They use a range of techniques including adult gene manipulation and hypothalamic implants to explore appetite and energy regulation mechanisms.

They have recently discovered the important role played by peripheral peptide hormonal signals in the gut in controlling appetite.

Prof Bloom has received the funding for developing the naturally occurring gut hormone pancreatic polypeptide (PP). Prof Bloom was keen to use something that the body itself produces to regulate appetite as opposed to a potentially toxic drug. He is of the view this method would not have the side effects of current obesity drugs such as Sanofi-Aventis's Acomplia.

"Developing a treatment based on natural appetite suppression, mimicking our body's response to being full, has the potential to be safe and effective," says Professor Bloom. "We believe that pancreatic polypeptide may be the answer."

He is hoping that eventually the compound could be used in a pen-based applicator, similar to the one for insulin, and that it could be available within 5 to 8 years, and eventually a chewing gum based or nasal spray version could also be available.

Over 1,000 people die prematurely from obesity in the UK each week, and according to their website, there are no effective treatments, a fact that spurs Prof Bloom and his team on to do this work.

Two other funds have also been awarded by the Wellcome Trust under its Seeding Drug Discovery Initiative, one to a Bristol University team who are working on a new way to switch off cancer tumour cells, and another to the biotech company Prolysis who is working on a way to prevent MRSA bacteria from getting hold of a protein they use to replicate themselves.

Wellcome's intention with this type of funding is to bridge the gap between the small grants awarded by government and the larger funds from private capital such as venture capitalists who tend to wait until the later, less risky stages of drug development.

Ted Bianco who is Wellcome's director of technology transfer, said that the aim was to get "more players involved in the business of drug discovery".

Imperial College, London (Faculty of Medicine)

Wellcome Trust Seeding Drug Discovery Initiative

Written by: Catharine Paddock
Writer: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

• Additional
• References
• Citations